{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:47:31Z","timestamp":1792162051187,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Metaplastic breast carcinoma (MpBC) is a rare and aggressive subtype of breast cancer, often characterized by triple-negative (TN) receptor status and a limited response to standard chemotherapy. The optimal treatment strategy remains undefined. This study evaluates overall survival (OS) in patients with TN-MpBC treated with neoadjuvant chemotherapy (NAC) or neoadjuvant chemo-immunotherapy (NACIO) compared with upfront surgery using the National Cancer Database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort analysis was conducted using the National Cancer Database to identify patients diagnosed with stage I\u2013III TN-MpBC between 2010 and 2022 and treated with NAC, NACIO, or upfront surgery. Primary endpoints included OS, pathologic complete response (pCR), and breast conservation rates. Continuous variables were analyzed using the Wilcoxon rank-sum test, and categorical variables were assessed with the chi-squared or Fisher\u2019s exact test. Survival was estimated using the Kaplan\u2013Meier method. Breast conservation and pCR were analyzed using logistic regression, and OS was analyzed using a Cox proportional hazards model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 4953 patients, 3429 (69.2%) underwent upfront surgery, 1232 (24.9%) received NAC, and 292 (5.8%) received NACIO. No significant difference in OS was observed between NACIO and surgery-first approaches (hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.51\u20131.27;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.3), but NAC was associated with a 37% increased risk of mortality compared with upfront surgery (HR 1.37; 95% CI 1.21\u20131.56;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). NACIO was associated with a 62% higher likelihood of achieving pCR than was NAC (odds ratio [OR] 1.62; 95% CI 1.11\u20132.38;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.013). The rate of breast conservation was not significantly different between NACIO and upfront surgery (OR 0.8; 95% CI 0.61\u20131.05;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.11), but patients receiving NAC were 27% less likely to undergo breast-conserving surgery than were those undergoing upfront surgery (OR 0.73; 95% CI 0.63\u20130.84;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Stage significantly modified the association between treatment strategy and breast conservation (pooled Wald test,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.022).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with TN-MpBC, NACIO demonstrated survival outcomes comparable to those with upfront surgery and improved pCR rates compared with NAC. These findings suggest that integrating immunotherapy into neoadjuvant treatment may offer clinical benefit, warranting further prospective investigation. However, findings should be interpreted cautiously given the baseline stage differences between the treatment groups and the potential for residual confounding inherent to retrospective database studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20713-1","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:09:28Z","timestamp":1792159768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Chemo-Immunotherapy Yields Survival Comparable to Upfront Surgery in Metaplastic Breast Cancer: A National Cancer Database Analysis"],"prefix":"10.1245","author":[{"given":"Margo","family":"Nelis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayakrishna K.","family":"Gadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Chichura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"20713_CR1","unstructured":"Breast Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 3.2026- May 20, 2026"},{"key":"20713_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103924","volume":"182","author":"HR Thomas","year":"2023","unstructured":"Thomas HR, Hu B, Boyraz B, et al. Metaplastic breast cancer: A review. Crit Rev Oncol Hematol. 2023;182:103924. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103924.","journal-title":"Crit Rev Oncol Hematol."},{"key":"20713_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/tbj.13234","volume":"25","author":"S Takala","year":"2019","unstructured":"Takala S, Heikkil\u00e4 P, Nevanlinna H, Blomqvist C, Mattson J. Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease. Breast J. 2019;25:418\u201324. https:\/\/doi.org\/10.1111\/tbj.13234.","journal-title":"Breast J."},{"issue":"1","key":"20713_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clbc.2025.06.002","volume":"26","author":"CC Hettwer","year":"2026","unstructured":"Hettwer CC, Wurschi GW, Pietschmann K. A systematic review with individual patient data meta-analysis on characteristics and outcomes of patients with metaplastic breast carcinoma. Clin Breast Cancer. 2026;26(1):139\u201349. https:\/\/doi.org\/10.1016\/j.clbc.2025.06.002.","journal-title":"Clin Breast Cancer."},{"issue":"5","key":"20713_CR5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.clbc.2017.04.009","volume":"17","author":"D El Zein","year":"2017","unstructured":"El Zein D, Hughes M, Kumar S, et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clin Breast Cancer. 2017;17(5):382\u201391. https:\/\/doi.org\/10.1016\/j.clbc.2017.04.009.","journal-title":"Clin Breast Cancer."},{"issue":"3","key":"20713_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-010-0780-8","volume":"120","author":"SY Jung","year":"2010","unstructured":"Jung SY, Kim HY, Nam BH, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010;120(3):627\u201337. https:\/\/doi.org\/10.1007\/s10549-010-0780-8.","journal-title":"Breast Cancer Res Treat."},{"issue":"52","key":"20713_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002341","volume":"94","author":"A Aydiner","year":"2015","unstructured":"Aydiner A, Sen F, Tambas M, Ciftci R, Eralp Y, Saip P, et al. Metaplastic breast carcinoma versus triple-negative breast cancer: survival and response to treatment. Medicine (Baltimore). 2015;94(52):e2341.","journal-title":"Medicine (Baltimore)."},{"issue":"11","key":"20713_CR8","doi-asserted-by":"publisher","first-page":"8525","DOI":"10.1245\/s10434-025-18085-z","volume":"32","author":"AM Chichura","year":"2025","unstructured":"Chichura AM, Chen X, Nelis M, et al. Neoadjuvant chemotherapy is associated with worse 5-year overall survival in patients with metaplastic breast cancer compared with primary surgery: a National Cancer Database analysis. Ann Surg Oncol. 2025;32(11):8525\u201333. https:\/\/doi.org\/10.1245\/s10434-025-18085-z.","journal-title":"Ann Surg Oncol."},{"key":"20713_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s10549-019-05264-2","volume":"176","author":"Z Al-Hilli","year":"2019","unstructured":"Al-Hilli Z, Choong G, Keeney MG, et al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019;176:709\u201316. https:\/\/doi.org\/10.1007\/s10549-019-05264-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"20713_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10549-011-1686-9","volume":"130","author":"IC Chen","year":"2011","unstructured":"Chen IC, Lin CH, Huang CS, Lien HC, Hsu C, Kuo WH, Lu YS, Cheng AL. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011;130(1):345\u201351.","journal-title":"Breast Cancer Res Treat."},{"issue":"9","key":"20713_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med."},{"key":"20713_CR12","doi-asserted-by":"crossref","unstructured":"Song Y, Liu X, Zhang G, et al. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol. 2013; 11:129-7819- 11-129.","DOI":"10.1186\/1477-7819-11-129"},{"key":"20713_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/jclinpath-2011-200586","volume":"65","author":"H Lee","year":"2012","unstructured":"Lee H, Jung S-Y, Ro JY, et al. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol. 2012;65:441\u20136.","journal-title":"J Clin Pathol."},{"issue":"2","key":"20713_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.60312","volume":"8","author":"K Demarest","year":"2025","unstructured":"Demarest K, Anantharajah A, Maxwell KN, et al. Pathogenic germline variants in patients with metaplastic breast cancer. JAMA Netw Open. 2025;8(2):e2460312. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.60312.","journal-title":"JAMA Netw Open."},{"key":"20713_CR15","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1158\/1078-0432.CCR-21-3100","volume":"28","author":"C Yam","year":"2022","unstructured":"Yam C, Abuhadra N, Sun R, et al. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res. 2022;28:2878\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3100.","journal-title":"Clin Cancer Res."},{"issue":"5","key":"20713_CR16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ijrobp.2024.06.016","volume":"120","author":"LFN Yit","year":"2024","unstructured":"Yit LFN, Quek ZHS, Tan TJ, et al. Curative approaches for metaplastic breast cancer: a retrospective cohort outcome review. Int J Radiat Oncol Biol Phys. 2024;120(5):1273\u201383. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.06.016.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"20713_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10549-008-0197-9","volume":"117","author":"B Weigelt","year":"2009","unstructured":"Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2009;117(2):273\u201380. https:\/\/doi.org\/10.1007\/s10549-008-0197-9.","journal-title":"Breast Cancer Res Treat."},{"issue":"7","key":"20713_CR18","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3390\/cancers12071832","volume":"12","author":"S Gonz\u00e1lez-Mart\u00ednez","year":"2020","unstructured":"Gonz\u00e1lez-Mart\u00ednez S, P\u00e9rez-Mies B, Carretero-Barrio I, et al. Molecular features of metaplastic breast carcinoma: an infrequent subtype of triple negative breast carcinoma. Cancers (Basel). 2020;12(7):1832. https:\/\/doi.org\/10.3390\/cancers12071832.","journal-title":"Cancers (Basel)."},{"issue":"11","key":"20713_CR19","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/s41416-020-01065-3","volume":"123","author":"E Kalaw","year":"2020","unstructured":"Kalaw E, Lim M, Kutasovic JR, et al. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. Br J Cancer. 2020;123(11):1665\u201372.","journal-title":"Br J Cancer."},{"key":"20713_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","volume":"28","author":"S Adams","year":"2022","unstructured":"Adams S, Othus M, Patel SP, et al. A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609). Clin Cancer Res. 2022;28:271\u20138.","journal-title":"Clin Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20713-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20713-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20713-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:09:29Z","timestamp":1792159769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20713-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":20,"alternative-id":["20713"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20713-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Vijayakrishna Gadi has received consulting fees (e.g., for participation on advisory boards) from Puma Biotechnology, Daiichi Sankyo, Novartis, AstraZeneca, Genentech, Bayer, Gilead, Hologic, Lilly, and Pfizer; has received payment for contracted research to their institution from Illumina, Novartis, Lilly, Gilead, Agendia, Genentech, and Phrontline; and is a stock shareholder with individual stocks and\/or stock options in Tempus.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}